Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.

Launch Date: November 25, 2024

Release Date: November 25 2024

Expiration Date: October 31, 2025

FACULTY

Scott Canna, MD

Assistant Professor of Pediatrics

Childrens Hospital of Philadelphia

Pui Lee, MD

Assistant Professor of  ...